Immunitas Therapeutics, Inc. is a biotechnology company focused on developing therapies for chronic inflammatory and autoimmune diseases. The company’s pipeline includes a preclinical antibody program that selectively targets pathogenic cells at sites of inflammation, aiming for deeper and more durable disease control in patients who do not respond adequately to existing treatments.
Global license of a preclinical antibody that targets pathogenic cells at inflammation sites to provide durable control in chronic immune diseases; includes milestones to €407.5M +royalties
